Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 pre-specified symptom endpoints.

VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be ...

Analysts displayed cautious optimism, focusing on the progress of clinical trials and upcoming ... and manufacturing agreements for Phase 3 trials. The current quarter saw heightened activity ...

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 ... or completed clinical trials exploring the ...

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for ...

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the ...

"This level of cooperation will streamline trial operations ... advance its Phase 3 program," said Kimball A. Johnson, M.D., Medical Director of CenExel iResearch Atlanta. "Cedar Clinical Research ...

Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Dr. DeWeese has no relationship with Candel, other than serving as the national principal investigator for Candel’s phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk ...

Two novel agents targeting angiopoietin-like protein 3 demonstrated safety and lipid-lowering capabilities in phase 2 trials, ...